search
Back to results

Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic Endometritis

Primary Purpose

Chronic Endometritis

Status
Recruiting
Phase
Phase 2
Locations
Greece
Study Type
Interventional
Intervention
Intrauterine infusion
Oral administration
Sponsored by
Genesis Athens Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Endometritis

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Positive diagnosis of CE following hysteroscopy and endometrial biopsy (positive diagnosis is required by both evaluations)
  • Signed Informed Consent
  • 18.5 < BMI < 30

Exclusion Criteria:

  • Diagnosed endometriosis or other related Pelvic Inflammatory Disorder (PID)
  • Current or previous cancer diagnosis
  • Auto-immune or genetic disorders
  • Menstrual cycle disorders

Sites / Locations

  • Genesis ACRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Intrauterine infusion of antibiotics

Combination of intrauterine infusion and oral administration of antibiotics

Oral administration of antibiotics

Arm Description

Thirty women will receive only intrauterine infusion of antibiotics for 30 days.

Thirty women will receive a combination of intrauterine infusion and oral administration of antibiotics for 30 days.

Thirty women will receive only oral administration of antibiotics for 30 days.

Outcomes

Primary Outcome Measures

Negative diagnosis of CE following hysteroscopy and endometrial biopsy
All participants will be subjected to hysteroscopy and endometrial biopsy following completion of treatment. Regarding hysteroscopy the presence of endometritis will be evaluated according to the published unified diagnostic criteria for CE. The endometrial biopsy will be performed employing a pipelle. To minimize contamination risk, following the placement of a vaginal speculum and cleaning external uterine ostium with an iodine solution, the pipelle will be inserted under visual control into the uterine cavity ensuring avoidance of any contact with vaginal walls. Endometrial samples will be diluted into 2 ml of saline for histological analysis. For histological analysis the endometrium samples will be fixated employing neutral formalin and paraffin. To stain the microsections, hematoxyline and eosin will be engaged. CD138 staining will be performed and positivity will indicate a CE diagnosis (>1 plasma cell per 10HPFs). A negative CE diagnosis should be confirmed by both assessments

Secondary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
Number of reports of side-effects according to CTCAE v6.0 per treated patients

Full Information

First Posted
December 23, 2021
Last Updated
February 22, 2023
Sponsor
Genesis Athens Clinic
Collaborators
National and Kapodistrian University of Athens
search

1. Study Identification

Unique Protocol Identification Number
NCT05205993
Brief Title
Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic Endometritis
Official Title
Investigating the Effectiveness of Innovative Intrauterine Antibiotic Therapy for the Treatment of Patients With Chronic Endometritis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2021 (Actual)
Primary Completion Date
January 30, 2024 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Genesis Athens Clinic
Collaborators
National and Kapodistrian University of Athens

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Chronic Endometritis (CE) is related to infertility and entails a challenging management. This study investigates the treatment of off-label intrauterine antibiotic infusion either separately or combined with oral antibiotic administration, and it assesses respective performance against the gold standard treatment of oral antibiotic adminstration. Data sourced herein reports on treatment efficiency, defined as a negative diagnosis for chronic endometritis.
Detailed Description
An infectious endometrial environment caused by certain pathologies could compromise establishment of the initial interaction between the embryo and the endometrium. Chronic endometritis (CE) is a case of a persistent endometrial inflammation caused by infectious agents namely Escherichia Coli, Enterococcus faecalis, Streptococcus agalactiae, Mycoplasma, Ureaplasma, and Chlamydia. The perplexity of managing CE is attributed to its asymptomatic nature rendering a definitive diagnosis rather challenging. The list of potential symptoms is limited and vague while manifestation of the disease may be mild and may not correspond to severity. Symptoms include pain in the pelvic cavity, dispareunia, uterine bleeding, vaginal infections and cystitis, and mild gastro-intestinal discomfort. CE is described as a chronic disorder due to its long duration and persistent nature, with potentially slow progression and complex causality, severely compromising reproductive potential of patients. The antibiotic treatments are primarily administered orally and endometrial re-examination is performed following treatment. It should be emphasized that apart from the differences in the types of antibiotics included, there are also significant discrepancies regarding the dosage of each antibiotic and the different schemes suggested by each practice. Following the antibiotic regime, endometrial receptivity is anticipated to improve. However, a significant correlation between the antibiotic therapeutic approach and a positive results in IVF has failed to be established in literature, indicating that oral antibiotic administration is unseccessful in improving IVF outcome. A pilot study published by the investigators indicated that combination of intrauterine infusion of antibiotics and oral administration can be more effective in treating CE than solely oral administration. However, it has not been evaluated if sole intrauterine infusion of antibiotics can be of similar effectiveness when compared to the combined regime including intrauterine infusion and oral andministration, or when compared to the gold standard treatment including only oral administration of antibiotics.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Endometritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intrauterine infusion of antibiotics
Arm Type
Experimental
Arm Description
Thirty women will receive only intrauterine infusion of antibiotics for 30 days.
Arm Title
Combination of intrauterine infusion and oral administration of antibiotics
Arm Type
Experimental
Arm Description
Thirty women will receive a combination of intrauterine infusion and oral administration of antibiotics for 30 days.
Arm Title
Oral administration of antibiotics
Arm Type
Active Comparator
Arm Description
Thirty women will receive only oral administration of antibiotics for 30 days.
Intervention Type
Drug
Intervention Name(s)
Intrauterine infusion
Intervention Description
A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Intervention Type
Drug
Intervention Name(s)
Oral administration
Intervention Description
per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day and metronidazole of 500mg twice a day for a total of 30 days
Primary Outcome Measure Information:
Title
Negative diagnosis of CE following hysteroscopy and endometrial biopsy
Description
All participants will be subjected to hysteroscopy and endometrial biopsy following completion of treatment. Regarding hysteroscopy the presence of endometritis will be evaluated according to the published unified diagnostic criteria for CE. The endometrial biopsy will be performed employing a pipelle. To minimize contamination risk, following the placement of a vaginal speculum and cleaning external uterine ostium with an iodine solution, the pipelle will be inserted under visual control into the uterine cavity ensuring avoidance of any contact with vaginal walls. Endometrial samples will be diluted into 2 ml of saline for histological analysis. For histological analysis the endometrium samples will be fixated employing neutral formalin and paraffin. To stain the microsections, hematoxyline and eosin will be engaged. CD138 staining will be performed and positivity will indicate a CE diagnosis (>1 plasma cell per 10HPFs). A negative CE diagnosis should be confirmed by both assessments
Time Frame
Negative diagnosis of CE will be assessed in one month -immidiately after treatment completion-.
Secondary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
Description
Number of reports of side-effects according to CTCAE v6.0 per treated patients
Time Frame
Side-effects will be monitored for one month from treatment initiation which is until completion of treatment

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Positive diagnosis of CE following hysteroscopy and endometrial biopsy (positive diagnosis is required by both evaluations) Signed Informed Consent 18.5 < BMI < 30 Exclusion Criteria: Diagnosed endometriosis or other related Pelvic Inflammatory Disorder (PID) Current or previous cancer diagnosis Auto-immune or genetic disorders Menstrual cycle disorders
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Konstantinos Sfakianoudis, MD
Phone
2106894326
Email
sfakianosc@yahoo.gr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Konstantinos Sfakianoudis, MD
Organizational Affiliation
Genesis Athens Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Genesis AC
City
Athens
ZIP/Postal Code
15232
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Panagiotis Tzonis, MD
Phone
6937115569
Email
ptzonis@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34341409
Citation
Pantos K, Simopoulou M, Maziotis E, Rapani A, Grigoriadis S, Tsioulou P, Giannelou P, Nitsos N, Tzonis P, Koutsilieris M, Sfakianoudis K. Introducing intrauterine antibiotic infusion as a novel approach in effectively treating chronic endometritis and restoring reproductive dynamics: a randomized pilot study. Sci Rep. 2021 Aug 2;11(1):15581. doi: 10.1038/s41598-021-95072-w.
Results Reference
background

Learn more about this trial

Εffectiveness of Intrauterine Antibiotic Administration for Treatment of Chronic Endometritis

We'll reach out to this number within 24 hrs